Go Deep
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -10,355 | -13.9 | 65.24 | 0.00 | 1,728.49 |
| Oct 2026 | -10,060 | -13.7 | 64.70 | 0.00 | 1,709.05 |
| Oct 2026 | -11,891 | -14.6 | 68.04 | 0.00 | 1,797.61 |
| Oct 2026 | -11,241 | -14.2 | 66.86 | 0.00 | 1,761.70 |
| Oct 2026 | -11,911 | -14.5 | 68.08 | 0.00 | 1,795.82 |
| Oct 2026 | -15,159 | -15.7 | 74.01 | 0.00 | 1,952.27 |
| Oct 2026 | -15,376 | -15.8 | 74.40 | 0.00 | 1,957.85 |
| Oct 2026 | -15,750 | -15.9 | 75.09 | 0.00 | 1,971.82 |
Nuvectis Pharma, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -7,020,000.0 | -6,050,000.0 | -7,314,000.0 | -7,462,000.0 |
| EPS | -0.3 | -0.3 | — | -0.4 |
Nuvectis Pharma, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -26,442,000.0 | -19,000,000.0 | -22,260,000.0 | -19,085,000.0 |
| EPS | -1.3 | -1.1 | -1.4 | -1.5 |
Nuvectis Pharma, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 31,709,000.0 | 18,607,000.0 | 19,185,000.0 | 20,405,000.0 | — |
| Total Liabilities | 13,296,000.0 | 8,894,000.0 | 6,984,000.0 | 6,186,000.0 | — |
| Total Equity | 18,413,000.0 | 9,713,000.0 | 12,201,000.0 | 14,219,000.0 | — |
Owes vs Owns
Nuvectis Pharma, Inc. owed $0.59 for every $1 it owned in Jun 2026, up from $0.30 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.59× | 0.42× | 0.48× | 0.36× | 0.30× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Nuvectis Pharma, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 99.8%
How it's funded — Dec 2025
Payables 19.8%Other liabilities 22.1%Shareholders' equity 58.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 31.6 | 18.5 | 19.1 | 20.0 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.1 | 0.1 | 0.1 | 0.4 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 6.3 | 2.5 | 2.8 | 2.9 |
| Other liabilities | 7.0 | 6.4 | 4.2 | 3.3 |
| Shareholders' equity | 18.4 | 9.7 | 12.2 | 14.2 |
| Net tangible assets | 18.4 | 9.7 | 12.2 | 14.2 |
Nuvectis Pharma, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -16,009,000.0 | -12,247,000.0 | -15,954,000.0 | -13,559,000.0 | — |
| Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Financing Activities | 29,110,000.0 | 11,654,000.0 | 15,087,000.0 | 27,810,000.0 | — |